Search Results
May 22, 2026, 07:00 ET BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
cancer. TET2 plays a key role in DNA demethylation, and its inhibition in tumors contributes to abnormal DNA hypermethylation. By reactivating TET2, GLIX1 increases DNA demethylation and triggers excessive base excision repair, leading to the accumulation of single-strand DNA breaks that ultimately convert
More news about: BioLineRx Ltd.; Hemispherian AS
May 22, 2026, 06:00 ET As Genetics Reshapes Healthcare, SCU Prepares Students for Growing Workforce
disease diagnostics, inherited cancer risk assessment, and genomic tools in research and clinical care.Emerging technologies such as advanced DNA analysis, gene editing, and the use of AI in genetic medicine are rapidly transforming how diseases are detected, understood, and treated. These advances
More news about: Southern California University of Health Sciences
May 22, 2026, 05:04 ET XJTLU celebrates 20th anniversary and unveils new 10-year plan
open and modern campus, and a highly internationalised educational approach.Looking ahead, he emphasised: "Innovation is forever embedded in the DNA of all XJTLUers."The anniversary celebrations also included the unveiling of commemorative gifts from the University's two parent institutions:
More news about: Xi'an Jiaotong-Liverpool University
May 22, 2026, 02:47 ET Gene Solutions 於 TJCC 2026 展示 AI 驅動多體學液態切片創新成果: 推動台灣精準腫瘤醫學發展
驅動整合型平台，該平台結合了多體學數據（基因體、表觀基因體、片段體和轉錄體）與臨床資料，在整個癌症照護旅程中提供可啟發臨床決策的關鍵洞察 —— 從用於多癌種早期檢測（MCED）的 SPOT-MAS，到結合 DNA+RNA 完整分析並搭載 AI 強化工具（如 OriCUP）與融合基因偵測的 K-TRACK 和
More news about: Gene Solutions Genomics Pte., Ltd
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Kelun-Biotech
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer.Saturday,
More news about: AbbVie
May 21, 2026, 18:08 ET MUSIC INDUSTRY LEADER PETER SHAPIRO JOINS TEACHROCK BOARD OF DIRECTORS
Browne, Martin Scorsese, and Bruce Springsteen, TeachRock was created to help address the student dropout crisis by keeping music and the arts in the DNA of education. What began as a mission to prevent disengagement has evolved into a movement—one that meets a generation of students growing up isolated,
More news about: TeachRock
May 21, 2026, 16:15 ET David P. King elected to Illumina's Board of Directors
IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
May 21, 2026, 16:05 ET Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
dysplasia.About INOVIO's DNA Medicines PlatformINOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are
More news about: INOVIO Pharmaceuticals, Inc.
May 21, 2026, 13:23 ET New report highlights gap between New GMO hype and global market reality
countries, including the United States, UK, Brazil, Argentina and Australia, have adopted regulatory frameworks that exempt new GMOs without foreign DNA from existing GMO regulations.In practice, this results in the removal of requirements for risk assessment, traceability and labelling, which
More news about: Non-GMO Project
May 21, 2026, 10:21 ET Volta Labs führt automatisierte Bibliotheksvorbereitungslösung für das Oxford Nanopore Ligation Sequencing Kit V14 ein
Volta Labs, Hersteller des Callisto™ Sample Prep System, gab heute die Verfügbarkeit seiner DNA Library Preparation Application für das Oxford Nanopore Technologies Ligation Sequencing Kit V14 (SQK-LSK114) bekannt. Das neue Callisto™-Probenvorbereitungsprotokoll,
More news about: Volta Labs
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Kelun-Biotech
May 21, 2026, 09:05 ET Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14
weight DNA extraction and ligation-based library preparation support routine whole genome sequencing within workflows aligned to ISO 15189 standards."As we evaluate whole genome sequencing for routine clinical diagnostics, having a robust, automated workflow is essential. Callisto's HMW DNA extraction
More news about: Volta Labs
May 21, 2026, 08:47 ET FDA Veteran Paz Vellanki, MD, PhD, Joins Precision for Medicine, Forming a Trio of Former Regulatory Leaders
welcome Paz to our team," said Harpreet Singh. "Her expertise in lung cancer, head and neck cancer, rare tumors and novel endpoints like circulating tumor DNA, combined with her years of experience shaping regulatory decisions inside the FDA, make her an extraordinary asset to our clients and to this organization."Dr.
More news about: Precision for Medicine
May 21, 2026, 04:05 ET Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14
weight DNA extraction and ligation-based library preparation support routine whole genome sequencing within workflows aligned to ISO 15189 standards."As we evaluate whole genome sequencing for routine clinical diagnostics, having a robust, automated workflow is essential. Callisto's HMW DNA extraction
More news about: Volta Labs
May 20, 2026, 16:28 ET De advogada a produtora rural: Flávia Garcia Cid transforma fazenda em referência nacional em óleos essenciais
jornada. Para a produtora, a trajetória comprova que "tudo é possível quando se coloca o coração e a dedicação ao trabalho".Tecnologia e ESG no DNAA Fazenda Jaracatiá opera com um modelo de negócios inovador e verticalizado. Flávia implementou uma indústria de destilação própria, desenvolvendo
More news about: Bayer
May 20, 2026, 09:01 ET DIESEL Fragrances unveils Dove Cameron as the Global Ambassador for ONLY DESIRE
and jewelry to interiordesign and real estate projects with Diesel Living. Discovering, supporting, and fostering creativity is part of Diesel DNA and of its parenting company OTB, the international fashion and luxury group powering a variety of global iconic brands and companies.
More news about: DIESEL Fragrances
May 20, 2026, 09:00 ET Smashburger® Bolsters Leadership Team with Three Executive Hires to Accelerate Franchise Expansion
and Darden Restaurants, leading fan activation for the brand's sports partnerships as well as menu innovation."Smashburger is a brand with deep DNA and an even deeper commitment to quality that delivers flavor that can't be replicated – not at home or in a drive-thru," said Savelli. "The smash sear
More news about: Smashburger
May 20, 2026, 09:00 ET LS Power Grid California Breaks Ground on Power the Bay Projects
together with a shared vision."Santa Clara Mayor Lisa Gillmor said, "Santa Clara has always led on clean, reliable energy, and it's in our DNA as home to Silicon Valley Power. These LS Power Grid California transmission projects strengthen the grid that powers our residents and businesses, meet
More news about: LS Power
May 20, 2026, 08:00 ET Quantiphi Appoints Jim Reesing as Chief Executive Officer to Scale Its Next Era of Enterprise AI Leadership
continuing to lead innovation, customer engagement and long-term strategy."This is an evolution of leadership structure, not a change in our DNA," Quantiphi Co-founder
More news about: Quantiphi
May 20, 2026, 08:00 ET Yellow Wood Partners Portfolio Company Scholl's Wellness Company (Dr. Scholl's) Acquires Performance Insole and Footwear Innovation Company VKTRY
that sell into a variety of consumer channels, including mass, drug, food, specialty, value, club, and e-commerce. Yellow Wood's Consumer Operating DNA® investment and operating strategy is based on utilizing the firm's functional operating resources to help maximize brand performance by driving organic
More news about: Yellow Wood Partners
May 20, 2026, 08:00 ET Scholl's Wellness Company Enters High-Growth Athletic Performance Category Through Acquisition of Premium Carbon Fiber Insole Company VKTRY
that sell into a variety of consumer channels, including mass, drug, food, specialty, value, club, and e-commerce. Yellow Wood's Consumer Operating DNA® investment and operating strategy is based on utilizing the firm's functional operating resources to help maximize brand performance by driving organic
More news about: Dr. Scholl's
May 20, 2026, 07:00 ET BioLineRx to Report First Quarter 2026 Results on May 27, 2026
life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1
More news about: BioLineRx Ltd.
May 20, 2026, 06:00 ET Discovery Life Sciences Launches IVDR-Compliant Luminos® Comprehensive with 7-to-10-Day Turnaround for EU Oncology Trials
the Panel Covers and Why It MattersThe Luminos® Comprehensive panel covers 164 genes across actionable oncogenes, tumor suppressor genes, DNA damage repair pathways, and emerging therapeutic targets. Established biomarkers (EGFR, KRAS, BRAF, PIK3CA, HER2, TP53) sit alongside less-charted targets
More news about: Discovery Life Sciences
May 19, 2026, 22:54 ET Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to
More news about: Co-Diagnostics